Alternative splicing of Toll-like receptor pathway mRNAs in lung immune cells from patients with ARDS.

Authors

William J Janssen, Matthew Lapinig, Elizabeth Wynn, Martin Aguilar, Kara J Mould, Patrick S Hume, Jazalle McClendon, Frank Fang-Yao Lee, Camille M Moore, Scott Alper

Published in

American journal of physiology. Lung cellular and molecular physiology. Jun 18, 2026. Epub Jun 18, 2026.

Abstract

Acute respiratory distress syndrome (ARDS) is characterized by robust inflammation in the lungs and systemic circulation. In this context, the Toll-like receptor (TLR) signaling pathway plays a major role, driving inflammation that promotes host defense but also causing pathological tissue damage. To limit excessive inflammation, TLR signaling must be tightly controlled. One mechanism that modulates TLR signaling is alternative splicing of TLR pathway pre-mRNAs, which balances production of positively acting inflammatory mediators with alternative splice forms that terminate inflammation. To determine whether altered TLR pathway splicing contributes to pathological inflammation in ARDS, we evaluated two central mediators of the TLR signaling pathway, the MyD88 signaling adapter and the IRAK1 signaling kinase, in leukocytes isolated from bronchoalveolar lavage (BAL) of ARDS patients. We found that MyD88 gene expression was decreased in BAL immune cells while IRAK1 gene expression was increased. In parallel, we monitored long pro-inflammatory (MyD88-L and IRAK1) and shorter anti-inflammatory (MyD88-S and IRAK1c) splice forms and determined that IRAK1 splicing was shifted in a pro-inflammatory direction in ARDS patients. Lastly, we evaluated relationships between MyD88 isoform levels in BAL leukocytes and clinical outcomes. We conclude that pre-mRNA splicing of TLR pathway genes is altered in lung immune cells in patients with ARDS, that monitoring splicing of these genes may provide important prognostic information, and that manipulating splicing of these genes may be a useful novel therapeutic approach that needs further investigation.

PMID:
42313146
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.